Oral dose regimen of ibrexafungerp (formerly SCY-078) identified for Phase 3 VVC development; Phase 3 on track for initiation in the fourth quarter of 2018
Development of ibrexafungerp intravenous (IV) formulation delayed
Continued progress in our strategy to expand the use of oral ibrexafungerp in multiple indications
Adequate funds to support operations into 2020
PR Newswire
JERSEY CITY, N.J., Aug. 9, 2018